M. L. Méndez-rekin lankidetzan egindako argitalpenak (16)

2015

  1. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial

    Journal of the American Society of Nephrology, Vol. 26, Núm. 1, pp. 220-229

2013

  1. Anti-inflammatory profile of paricalcitol in hemodialysis patients: A prospective, open-label, pilot study

    Journal of Clinical Pharmacology, Vol. 53, Núm. 4, pp. 421-426

2012

  1. Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study

    BMC Nephrology, Vol. 13, Núm. 1

2000

  1. Amino acid losses during hemodialysis with polyacrylonitrile membranes: Effect of intradialytic amino acid supplementation on plasma amino acid concentrations and nutritional variables in nondiabetic patients

    American Journal of Clinical Nutrition, Vol. 71, Núm. 3, pp. 765-773

1999

  1. Autosomal dominant polycystic kidney disease associated with familial sensorineural deafness

    Scandinavian Journal of Urology and Nephrology, Vol. 33, Núm. 1, pp. 63-65

  2. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure

    Scandinavian Journal of Urology and Nephrology, Vol. 33, Núm. 2, pp. 121-125

  3. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration

    American Journal of Kidney Diseases, Vol. 33, Núm. 3, pp. 458-463

1998

  1. Androgens for the treatment of anemia in peritoneal dialysis patients.

    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, Vol. 14, pp. 232-235

  2. Effects of losartan on the treatment of posttransplant erythrocytosis

    Clinical Nephrology, Vol. 49, Núm. 6, pp. 370-372

  3. Hypermagnesemia in CAPD. Relationship with parathyroid hormone levels

    Peritoneal Dialysis International, Vol. 18, Núm. 1, pp. 77-80

1997

  1. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD

    Clinical Nephrology, Vol. 48, Núm. 3, pp. 181-184

  2. Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients.

    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, Vol. 13, pp. 257-259

  3. Hemodialysis urea rebound and membrane biocompatibility: Accuracy of Kt/V estimations

    Artificial Organs, Vol. 21, Núm. 2, pp. 91-95

  4. Serum magnesium concentration and PTH levels. Is long-term chronic hypermagnesemia a risk factor for adynamic bone disease?

    Scandinavian Journal of Urology and Nephrology, Vol. 31, Núm. 3, pp. 275-280

1996

  1. Atherogenic lipid and lipoprotein parameters in HD patients [1]

    Dialysis and Transplantation

  2. Evaluacion del efecto hipotensor del felodipino en monoterapia y asociado a enalapril en la hipertension arterial esencial leve y moderada

    Nefrologia, Vol. 16, Núm. 3, pp. 261-264